Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Apr 1;4(2):229-31.
doi: 10.3978/j.issn.2072-1439.2012.01.03.

Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma

Yalei Zhang  1 , Haihong Yang, Meiling Zhao, Jianxing He
Affiliations
Case Reports

Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma

Yalei Zhang et al. J Thorac Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest.

Figures

Figure 1
Figure 1
Whole body PET/CT demonstrated a large heterogeneous lesion located in the right iliac foss.
Figure 2
Figure 2
Chest radiography before treatment shows no lung metastases.
Figure 3
Figure 3
Chest CT shows bilateral pneumothorax after three cycles of bevacizumab containing chemotherapy.
Figure 4
Figure 4
Chest radiography shows right pneumothorax after the fifth chemotherapy.
See this image and copyright information in PMC

References

    1. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22:351-355 - PubMed
    1. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-1847 - PubMed
    1. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66:999-1013 - PubMed
    1. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10:559-568 - PubMed
    1. Smevik B, Klepp O. The risk of spontaneous pneumothorax in patients with osteogenic sarcoma and testicular cancer. Cancer. 1982;49:1734-1737 - PubMed

Publication types